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Dendrimers are hyperbranched and perfectly defined macromolecules, constituted of branches 
emanating from a central core in an iterative fashion. Phosphorhydrazone dendrimers 
constitute a special family of dendrimers, possessing one phosphorus atom at each branching 
point. The internal structure of these dendrimers is hydrophobic, but hydrophilic terminal 
groups can induce the solubility of the whole structure in water. Indeed, the properties of these 
compounds are mainly driven by the type of terminal groups their bear; this is especially true 
for the biological properties. For instance, positively charged terminal groups are efficient 
for transfection experiments, as drug carriers, as anti-prion agents, and as inhibitor of the 
aggregation of Alzheimer’s peptides, whereas negatively charged dendrimers have anti-
HIV properties and can influence the human immune system, leading to anti-inflammatory 
properties usable against rheumatoid arthritis. This review will give the most representative 
examples of the biological properties of water-soluble phosphorhydrazone dendrimers, 
organized depending on the type of terminal groups they bear.
Uniterms: Dendrimers. Phosphorhydrazone dendrimers. Biological properties. 
Nanomedicine.
Dendrímeros são macromoléculas extremamente ramificadas e perfeitamente definidas 
constituídas de ramificações que partem de um foco central de uma forma iterativa. 
Dendrímeros de fosforidrazona constituem uma família especial de dendrímeros, que 
possuem um átomo de fósforo em cada ponto da ramificação. A estrutura interna destes 
dendrímeros é hidrofóbica, mas grupos hidrofílicos terminais podem induzir a solubilidade 
em água de toda estrutura. De fato, as propriedades destes compostos são principalmente 
orientadas pelos grupos terminais que apresentam, especialmente para as propriedades 
biológicas. Por exemplo, grupos terminais carregados positivamente são eficientes para 
experimentos de transfecção, como transportadores de fármacos, agentes antipríons e como 
inibidores da agregação de peptídeos do Alzheimer, enquanto que dendrímeros carregados 
negativamente têm propriedades anti-HIV e podem influenciar o sistema imune humano, 
levando propriedades antiinflamatórias úteis contra artrite reumatoide. Essa revisão dará os 
exemplos mais representativos das propriedades biológicas de dendrímeros de fosforidrazona 
solúveis em água, organizados de acordo com os grupos terminais que possuem.
Unitermos: Dendrímeros. Dendrímeros de fosforidrazona. Propriedades biológicas. 
Nanomedicina.
INTRODUCTION
Dendrimers are at the forefront of research since almost two decades, 
due to the numerous properties they afford in different fields, such as ca-
talysis, materials, and biology to name as a few (Caminade et al., 2011). 
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Their name has been created by D.A. Tomalia (Tomalia et 
al., 1985) from two Greek words: dendros (tree) and meros 
(part), which emphasize first their shape and then their 
chemical structure. Indeed, dendrimers are composed of 
identical branches constituted of monomers, and emanat-
ing radially from a central core. Contrarily to all the other 
types of polymers, dendrimers are not synthesized by 
polymerization reactions but step-by-step. Such methodol-
ogy allows a perfect control over the whole structure. The 
most widely used methods of synthesis of dendrimers are 
divergent methods. In this case, the structure is grown from 
the core towards the terminal groups, layer after layer. 
Each time a new layer of branching points is created, a new 
generation is obtained. The following Figure 1 displays the 
principle of the synthesis of dendrimers via a divergent 
process. Such process is compatible with different types 
of reactions; the only limitation is that the reactions must 
be quantitative. Indeed, it is impossible to purify a mixture 
containing a perfect dendrimer and a dendrimer in which 
one terminal function is missing, even if this defect can 
be detected (for instance by NMR).
The branching structure is widely found in the Na-
ture at the macroscopic level, for instance in the branches 
and roots of trees. However, at the molecular level, there 
is no example to date of a natural molecule having such a 
branched structure. This is certainly one of the reasons of the 
success of dendrimers in biology and nanomedicine (Rol-
land et al., 2009b). We will focus this review on the most 
salient biological properties of the phosphorhydrazone den-
drimers that we synthesize. These dendrimers are synthe-
sized starting from a trifunctional core (P(S)Cl3) (Lartigue 
et al., 1997), or a hexafunctional core (N3P3Cl6) (Launay et 
al., 1997) as shown in Figure 2. The phosphorhydrazone 
linkage (P-N-N=CH) is created by the condensation reac-
tion of a phosphorhydrazide with an alhedyde. The terminal 
groups are either aldehydes or P(S)Cl2 functions. Both are 
particularly reactive and can be modified at will.
The internal structure of these phosphorus den-
drimers is hydrophobic (Leclaire et al., 2004), thus solubil-
ity in water (Caminade, Majoral, 2005), which is needed 
for biological purposes (Caminade et al., 2010), must be 
afforded by the terminal groups. To achieve this goal, 
either positively or negatively charged compounds have 
been grafted as terminal groups (Caminade et al., 2009). 
Positive charges are afforded by ammonium derivatives, 
and negative charges are afforded either by carboxylic acid 
salts or phosphonic acid salts.
PHOSPHORHYDRAZONE DENDRIMERS EN-
DED BY AMMONIUM GROUPS
The reaction of N,N-diethylethylene diamine with 
the P(S)Cl2 terminations affords directly the terminal 
ammonium groups, as shown in Figure 3. These charged 
terminal groups induce the solubility in water of the whole 
structure. The generations 1 (12 ammonium groups) to 5 
(192 ammonium groups) have been tested as transfection 
agents to deliver the luciferase plasmid into 3T3 cells. A 
clear influence of the generation of the dendrimer on the 
transfection efficiency, with an identical charge ratio in 
all cases (5:1 or 10:1 for ammonium from the dendrimer/
phosphate from the plasmid). From generations 1 to 4, an 
increase of the transfection efficiency is observed then a 
plateau is reached (Loup et al., 1999); the efficiency of 
dendrimers G4
+ and G5
+ is comparable to that of polyeth-
yleneimine (PEI), one of the chemical standards used in 
transfection experiments.
These first experiments have been extended to check 
the ability of the G4
+ dendrimer to interact with the fluo-
rescent probe 8-anilino-1-naphthalenesulfonate (ANS), 
the antineoplasic drug cisplatin, and the anti-HIV siRNA 
siP24, and also to check its capability to deliver the green 
fluorescent protein gene (pGFP) into cells (Shcharbin 
et al., 2011). The usefulness of G4+ to deliver specific 
siRNA against HIV-1 (siNEF) in PBMCs to interfere in 
HIV-1 replication was also assessed. The dendriplex G4
+/
siNEF showed a high efficiency in Nef silencing, and 
significantly reduced the viral replication. These results 
FIGURE 1 - The principle of the divergent synthesis of dendrimers.
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FIGURE 2 - Method of synthesis of phosphorhydrazone dendrimers, starting from the hexafunctional core.
constitute a potential alternative therapy in the HIV-1 
infection (Briz et al., 2012).
An analogous series of dendrimers, ended by the 
same ammonium groups, but built from a fluorescent 
phthalocyanine core (Leclaire et al., 2005) instead of the 
cyclotriphosphazene core, was used to detect its behavior 
in biological media. It was shown that this dendrimer 
alone can penetrate in human cells, and that it goes in-
side the cytoplasm (Maszewska et al., 2003). Grafting a 
maleimide fluorophore to the cyclotriphosphazene core 
of a second generation dendrimer allowed to studying 
its interaction with DNA (Kazmierczak-Baranska et al., 
2010). Several other types of ammonium terminated 
dendrimers were synthesized using the same type of ex-
periments from the P(S)Cl2 terminal groups. Pyrrolidine, 
morpholine, methyl piperazine, or phenyl piperazine 
derivatives have been grafted (Padie et al., 2009), but 
none of them were more efficient than the first one for 
transfection experiments.
The series of dendrimers displayed in Figure 3 was 
also shown to be efficient against various strains of the 
scrapie form of prions, including the one that causes the 
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“mad cow” disease (Bovine Spongiform Encephalopathy, 
BSE). The efficiency depends on the generation, but not in 
a linear fashion: generations 3 and 5 have a weak activity, 
whereas generation 4 (G4
+) is highly active. This genera-
tion 4 (Figure 3) was so efficient on the various strains of 
prions tested, that it has been tested also in vivo. Mice were 
infected by cells coming from the brain of terminally-ill 
mice. Some of them received every two days an intrave-
nous injection (iv) of 100 µg of the G4
+ dendrimer. After 
one month, all the treated mice were alive, and the quantity 
of the scrapie form of prion has decreased by 80% in their 
spleen, compared to untreated mice (Solassol et al., 2004). 
Using spin-probe and spin-label techniques, the interaction 
of the same polycationic dendrimers with the PrP 106–126 
peptide (prion peptide), was studied by EPR (Electron 
Paramagnetic Resonance) (Klajnert et al., 2007a). The 
FIGURE 3 - Method of synthesis of dendrimers ended by ammonium groups, and full chemical structure of the corresponding 
generation 4 (G4
+) phosphorus dendrimer.
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influence of the same dendrimer on the aggregation of 
the prion peptide PrP 185-208 was also assessed; G4
+ was 
able to clearly interfere with the PrP 185-208 aggregation 
process by both slowing down the formation of aggre-
gates and by lowering the final amount of amyloid fibrils 
(Klajnert et al., 2007b). It was shown that the polycationic 
dendrimers interact directly with heparin, and that this 
process is indirectly responsible for the inhibition of fibril 
formation by dendrimers (Klajnert et al., 2009).
Another aspect of this work concerns the study of the 
influence of the polycationic dendrimers on the aggregation 
of the peptide involved in the Alzheimer’s disease. In the 
case of the Aβ 1-28 peptide, the phosphorus dendrimers of 
generation 5 (G5
+) interacts with amyloid monomers and, 
consequently, fibril formation (which is a hallmark of the 
disease) is prevented, as shown by an EPR study (Ottaviani 
et al., 2010). A deeper insight on the process showed that 
it depends on the concentration in dendrimer, but not in 
a linear fashion. At low concentration of G3
+ or G4
+ den-
drimers (0.01 µM), the aggregation process is increased; 
at moderate concentration in dendrimers (0.1 µM), there is 
practically no influence on the aggregation process; at high 
concentration (1 or 10 µM), there is no trace of aggrega-
tion. These dendrimers modify also the aggregation of the 
MAP-Tau protein, and reduce toxicity caused by aggregated 
forms of Aβ 1−28 (Wasiak et al., 2012). The effect of the 
same dendrimers (generations G3
+ or G4
+) on the fibrillation 
of α-synuclein (ASN) was also tested. The inhibition of 
fibril formation (filamentous and aggregates) is a potential 
therapeutic strategy for neurodegenerative disorders such as 
Parkinson’s disease. The interaction between phosphorus-
containing dendrimers and ASN was studied. The results 
showed that the phosphorhydrazone dendrimers inhibited 
fibril formation, when they were used in the ASN/dendrimer 
ratios 1:0.1 and 1:0.5 (Milowska et al., 2012).
In view of all these biological properties of these poly-
cationic phosphorhydrazone dendrimers, their cytotoxicity 
and genotoxicity were assessed in human mononuclear 
blood cells, A549 human cancer cells and human gingival fi-
broblasts (HGFs). Dendrimers G3
+ and G4
+ at concentrations 
up to 10 μM induced a concentration dependent decrease in 
cell viability. They did not induce breaks in isolated DNA, 
but they induced DNA cross-links in the cells. The cells 
showed changes in their morphology, including loss of 
cell attachment, disruption of cell membrane and nucleus 
condensation (Gomulak et al., 2012). These compounds 
alone are toxic for these cells, as expected for polycationic 
compounds (Fischer et al., 2003), but their interaction with 
DNA decreases the toxicity, and the in vivo tests carried out 
in the case of the prion disease with the same dendrimer did 
not display any toxicity.
PHOSPHORHYDRAZONE DENDRIMERS EN-
DED BY CARBOXYLATE GROUPS
Negatively charged compounds are generally con-
sidered as less toxic than positive ones, thus we have also 
synthesized phosphorhydrazone dendrimers bearing nega-
tive charges on their terminal groups. In the first example, 
carboxylic acid functions have been obtained by a Doe-
bner-like reaction, from the aldehyde terminal functions, 
in the presence of CH2(CO2H)2, pyridine and piperazine 
(Figure 4) (Boggiano et al., 2000). The dendrimers ended 
by the carboxylic acid groups are not soluble in water, but 
the corresponding salts are indeed soluble. These salts can 
be obtained by reaction with sodium hydroxide, but also 
by acidobasic reactions with primary or secondary amines. 
These reactions have been carried out in particular with 
the galactosylceramide (galβ1cer) analog hexadecylami-
nolactitol, as chimera for the HIV virus. These supramo-
lecular assemblies are shown in Figure 4 for a dendrimer 
of second generation, built from a trifunctional core. Fur-
thermore these assemblies spontaneously self-assemble in 
bilayer vesicles (Blanzat et al., 2002). These compounds 
built from a trifunctional core, and the analogous series 
built from the hexafunctional cyclotriphosphazene core 
were synthesized with the goal of blocking HIV infection 
prior to the entry of the virus into human cells. Antiviral 
assays confirmed the crucial roles played both by mul-
tivalency effects and lipophilicity on the biological activ-
ity of Galβ1cer analogues. Furthermore the shape of the 
dendrimers is also a very important criterion, since the 
second generation built from the trifunctional core and 
the first generation built from the hexafunctional core, 
both decorated with 12 hexadecylaminolactitol moieties, 
exhibit very different IC50 values of 1.1 and 0.12 mM, 
respectively (Blanzat et al., 2005).
An analogous process was applied for the ocular 
delivery of carteolol, which is an ocular anti-hypertensive 
drug used to treat glaucoma. The dendrimers were designed 
with the aim of increasing the residence time of carteolol in 
the eyes, and in order to replace benzalkonium, which is a 
preservative. For this purpose, an ammonium was used as 
core, and carboxylic acid functions were chosen as terminal 
groups, but they were obtained in a different way than previ-
ously. The first step is the grafting of tertiobutyl benzoate 
on the P(S)Cl2 functions, then the deprotection provides the 
carboxylic acid derivatives. Reaction with the neutral form 
of carteolol affords the supramolecular assembly as shown 
in Figure 5 for the first generation. Generations 1 and 2 are 
poorly soluble in water, whereas generation 0 is fairly solu-
ble. These dendrimers have been tested in vivo, as vehicles 
for ocular drug delivery of carteolol to rabbits. No irritation 
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of the rabbit eyes was observed, whatever the dendrimer 
salt used and even after several hours. Due to the very low 
solubility of the second generation, the quantity of carteolol 
instilled is low, but the quantity of carteolol that penetrates 
inside the eyes is larger than expected, when compared with 
carteolol alone (2.5 times larger). These pharmacodynamic 
observations highlight the biocompatibility and the potential 
usefulness of the phosphorhydrazone dendrimers for drug 
delivery (Spataro et al., 2010).
PHOSPHORHYDRAZONE DENDRIMERS EN-
DED BY PHOSPHONATE GROUPS
The structure of the supramolecular assemblies 
against HIV shown in Figure 4 has been modified in order 
to try to increase their efficiency. In particular, the carbox-
ylic acid functions have been replaced by various types of 
phosphonic acids, in which an alkyl chain of variable length 
(up to C10) has been added to try to increase the strength of 
the association with the hexadecylaminolactitol (some ex-
amples are shown in Figure 6). Despite important structural 
differences on the terminal groups, these supramolecular 
assemblies have a comparable anti-HIV-1 activity. All 
compounds have submicromolar IC50 values in a cell-based 
HIV-infection model, but these compounds were found 
toxic (Perez-Anes et al., 2010). On the other hand, it was 
shown that the sodium salts of these dendrimers (without 
the hexadecylaminolactitol) have also anti-HIV properties, 
and are non toxic at concentrations up to 1 10-4 mol.L-1. 
Studying the influence of the length of the alkyl chain (R in 
Figure 6) afforded surprising results. The inhibitory activity 
of compounds in which R = H and R = C10H21 is comparable 
FIGURE 4 - Synthesis of a dendrimer ended by carboxylic acids, and its use for association with a Galactosylceramide analog, 
hexadecylaminolactitol.
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(around 2 10-5 mol.L-1), whereas that of the dendrimer hav-
ing a C3 alkyl chain was found to be 10 fold better (1.6 10-6 
mol.L-1) (Perez-Anes et al., 2009).
We have also synthesized as shown in Figure 7 
dendrimers ended by azabisphosphonic terminal groups, 
called ABP (for AzaBisPhosphonic). This dendrimer 
displays a lot of very important and original properties 
towards the human immune system, and particularly the 
human PBMCs (peripheral blood mononuclear cells). 
The first property discovered concerns the amplification 
of a special type of PBMCs that are the Natural Killer 
(NK) cells. These NK cells are especially important to 
fight against viral and bacterial infections, and above 
all, against many different types of cancers. However, 
before our work, their multiplication was difficult and 
necessitated complex, expensive and poorly available 
biological molecules/entities. The first generation of the 
dendrimer ABP shown in Figure 7 is able to multiply by 
several hundreds the number of NK cells in the blood 
samples coming from several donors, after 21 days in 
cultures. The bioactivity of the NK cells generated in 
the presence of dendrimers is not modified; cultures with 
these dendrimers did not induce activation or inhibition 
of the NK cells lytic response nor compromise direct 
toxicity for their target cells (7 leukemia and 7 carcinoma 
strains tested) and preserve autologous lymphocytes (no 
risk of induction of auto-immune disease). Different 
generations (zero, one, and two) were studied but the 
most efficient dendrimer is the first generation ended by 
the azabisphosphonic pincer (ABP) shown in Figure 7 
(Griffe et al., 2007).
In the search for the mechanism of action of this ABP 
dendrimer, it was discovered that the first interaction oc-
curs with monocytes, which are a pivotal cell population 
of innate immunity. In order to have a deeper insight on 
the mechanism, a fluorescent analogue of the dendrimer 
ABP was synthesized (statistical grafting of one fluores-
cein isothiocyanate (FITC) among the terminal groups). It 
was shown by confocal videomicroscopy that this tagged 
dendrimer binds to isolated monocytes and gets internal-
ized within a few seconds, following the phagolysosomial 
route for internalization. Here also, the dendrimer ABP 
was found the most efficient for the activation of mono-
cytes (Poupot et al., 2006). A large number of dendrimeric 
compounds ended by phosphonic acid salts have been 
synthesized. The modifications include the variation of 
the number of terminal groups, playing with the number 
of branches emanating from the cyclotriphosphazene core. 
Interestingly, it was shown that the dendrimer in which one 
branch is missing from the core has an analogous activity, 
opening the way to the possibility to graft specifically a 
fluorophore or a targeting entity (Rolland et al., 2008). 
Non-symmetrical azabisphosphonic salts as terminal 
groups (Marchand et al., 2009), but also dendrimers ended 
FIGURE 5 - Supramolecular assembly of a dendrimer ended by carboxylic acids and carteolol for ocular drug delivery.
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by isosteric functions (azabiscarboxylates and azabissul-
fonates) (Rolland et al., 2009a) have been synthesized. 
Some of the modified structures are shown in Figure 8, 
but none of them displayed better activities than the ABP 
dendrimer towards human PBMCs.
For a better understanding of the mechanism of ac-
tivation of monocytes by the ABP dendrimer, the gene ex-
pression was analyzed by Affimetrix arrays. It was found 
that 78 genes were up-regulated, whereas 62 genes were 
down-regulated. Analysis of these genes indicated that the 
human monocytes were activated through an alternative-
like, anti-inflammatory pathway. Furthermore, the ABP 
dendrimer induces an inhibition of the proliferation of the 
TCD4+ lymphocytes (pro-inflammatory lymphocytes) in 
IL2-stimulated PBMCs, without affecting their viability 
(Fruchon et al., 2009). This inhibition is one of the fac-
tors responsible for the NK cells enrichment (Portevin et 
al., 2009).
The ABP dendrimer also exhibited anti-osteoclastic 
activity (osteoclasts are giant cells responsible for bone 
resorption) on mouse and human cells, mediated by c-
FMS (cellular-feline McDonough strain sarcoma virus 
oncogene homolog) inhibition. Combination of the anti-
inflammatory and anti-osteoclastic properties suggests a 
possible use against rheumatoid arthritis (RA), which is 
an autoimmune inflammatory disorder characterized by 
inflammation of the synovial membrane, cartilage degra-
dation, and subsequent bone erosion by osteoclasts, lead-
ing to joint deformation and handicap. Weekly intravenous 
injections of dendrimer ABP at doses of 1 and 10 mg/kg 
inhibited the development of inflammatory arthritis in two 
animal models: IL-1ra−/− mice and mice undergoing K/
BxN serum transfer. Intravenous injections could be more 
inter-spaced (3 weeks, similar to anti-cytokine biothera-
pies). Interestingly, the same property against RA-like 
disease was observed when the ABP dendrimer was given 
orally. These preclinical assays suggest the potential use 
of dendrimer ABP as a nanotherapeutic for rheumatoid 
arthritis (Hayder et al., 2012).
CONCLUSION
We have shown in this review that the phosphorhy-
drazone dendrimers have many different potential appli-
cations for biology and nanomedicine. Indeed, depending 
on the nature of their terminal functions, their properties 
as transfection agents, as carriers of drugs, as anti-prion 
and anti-HIV agents, as inhibitor of the aggregation of 
Alzheimer’s peptides, as inhibitor or accelerator of prolif-
eration of human immune cells, and as anti-inflammatory 
drugs against rheumatoid arthritis have been already dem-
onstrated. All these tests confirm the high biocompatibility 
FIGURE 6 - Synthesis of dendrimers ended by phosphonic acids, and their association with the hexadecylaminolactitol.
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FIGURE 7 - Synthesis of the first generation dendrimer (ABP) ended by azabisphosphonic acid salts.
FIGURE 8 - Some examples of surface structural modifications relative to the ABP (Y = PO3HNa) dendrimer.
of these dendrimers, including for long term in vivo tests, 
despite their structure totally different in shape, size, and 
chemical composition, from that of any natural product. 
We do believe that these dendrimers are new and highly 
tunable nanotherapeutic candidates, and we do hope that 
the best is next to come.
A.-M. Caminade, C.-O. Turrin, J.-P. Majoral42
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